LATEST NEWS AND DEVELOPMENTS
IMPROVED PRODUCT WITH RECENT PRESENTED STUDY SUBMITTED
FOR CONSIDERATION BY
Professionals Treating Women & Men - Attending the American Academy of Dermatology
Conference in New Orleans - March, '99
HAIRPRIMEŽ SYSTEM FOR THINNING HAIR
"Conversion of Vellus Hair to Terminal Hair": A Closer Focus on the Success
After meeting and speaking with many of the dermatologists and health care
professionals attending the AAD Conference, the following are important points
to consider in determining whether women, as well as men, should view HairPrimeŽ
as a possible solution to their thinning hair or hair loss problems given that
there are only two FDA approved treatments for hair loss:
- Regardless of the hair growth claims by PropeciaŽ and MinoxidilŽ, no product
grows hair. If it were so, then hair should grow on the palms of your hand
and the bottoms of your feet when the product is applied. Hair grows on its
own from a healthy follicle. Products may only improve or enhance the environment,
health and condition of the follicle to allow the hair to grow.
- HairPrimeŽ, like PropeciaŽ and MinoxidilŽ, only creates a better environment
for growing hair. HairPrimeŽ is effective using natural botanical extracts
whereas the other two are synthetic. But most important
is the fact that women are warned not to use or handle PropeciaŽ and the additional
strength RogaineŽ with 5% MinoxidilŽ is indicated for men only.
- MinoxidilŽ, originally intended to treat blood pressure, was found to have
side effects which were positive on hair growth...HOWEVER, it does not block
the effects of DHT (the cause of androgenetic alopeciaŽ, commonly known as
"male pattern baldness", which effects both men and women), thus the hair
growth cycle is shortened. If the hair cycle is shortened, the hair will fall
out after only 3-5 weeks growth, rather than the normal healthy growth cycle
of 3-5 years. Thus, MinoxidilŽ may stimulate new hair growth, but it does
not extend the hair growth cycle to allow the vellus hair to convert to a
non-vellus/terminal, melanized, mature hair. [People who use MinoxidilŽ to
stimulate hair growth may find that using HairPrimeŽ will contribute to the
longer term life of the hair by converting the new growth hair to terminal
- DHT has been identified by researchers to cause the premature completion
of the growth phase of the hair growth cycle leading to the conversion of
hair follicles from the terminal form (which produces mature, pigmented hairs)
to the vellus form (which produces fine, short, "baby" hair). Thus, "thinning
hair" results from the inability of the hair to live and grow to full maturity
and "hair loss" logically results because the hair growth cycle is shortened
causing the hair to fall out prematurely.
- PropeciaŽ, employing FinasterideŽ (a drug originally
developed in ProscarŽ to treat the prostate), is claimed in research to inhibit
5 alpha reductase Type II, thus blocking the conversion of testosterone into
the androgen, DHT. HOWEVER, because 5 alpha reductase Type II is found mainly
in the genitalia tissue and PropeciaŽ invasively inhibits its activity, the
possible side effects of PSA masking and possible loss of libido in men are
logical. BUT MORE IMPORTANT, it poses a serious threat
to women of reproductive age as research has indicated that a deficiency
in DHT may cause the inability of a male fetus to form sex organs. Furthermore,
women after menopause may be effected by the increase in testosterone levels
because the conversion of DHT is blocked.
- Thus, if you dismiss the clinical effectiveness of HairPrimeŽ, as published
in a dermatologist peer review publication, The Journal
of Dermatological Treatment, then women have
only the choice of growing short, baby-fine hair that may last only
3-5 weeks with the use of 2% MinoxidilŽ.
- HairPrimeŽ is unique in that it is a SAFE, PROVEN,
NATURAL TREATMENT that WOMEN AND MEN can
use to convert vellus (fine, short, "baby") hair to non-vellus/terminal (mature,
full-grown, pigmented) hair because of its 5 alpha reductase inhibition like
activity which is TOPICALLY APPLIED. As a topical
application, HairPrimeŽ may seem cumbersome as it requires commitment, time
and compliance to achieve satisfactory results; but after satisfactory results
are achieved (as achieved by 80%-90% of those that have used HairPrimeŽ),
maintenance is much less time-consuming and the effects are long-term, not
transient. HairPrimeŽ is less invasive and less systemic than PropeciaŽ, although
PropeciaŽ may be easily ingested in seconds with effective results for men.
- Although on average there is a milder expression of hereditary hair thinning
in women, the emotional impact is often more devastating
to women than men. Men (from Yul Brenner to Telly Savalas to Michael
Jordon) have been able to transform their baldness into a fashion statement
whereas women have not had the same opportunities of emotional escape. Yet,
most of the marketing and development of hair loss treatment products are
focused on men. Our informal survey of women who have used HairPrimeŽ, even
those who have achieved satisfactory results, reveal that women are so self-conscious
about thinning hair that they will not participate in clinical tests or give
testimonials, especially where it exposes their results in public forums.
This is indeed a phenomenon as over 50% of our HairPrimeŽ customers are women.
- HairPrimeŽ, with your assistance, could be the leader in addressing hair
thinning/loss issues of women. Women, on average, prefer to avoid invasive
drugs in favor of natural treatments. If women use ethical natural products
with success, men may benefit in adopting the women's approach to regaining
aesthetic appearance as is the case where men have adopted the use of skin
care products that were previously only used by women.
To summarize, the key is not so much as to grow (new) hair, rather it is to
allow hair (whether new or old) to continue to grow healthy to full maturity.
Thus, we prefer to say "HairPrimeŽ Promotes a Healthy Environment for Hair to
Grow" rather than claiming that it grows hair.
I hope that this scientific distinction regarding "Conversion To Terminal Hair"
that we have delivered at the IBC Scientific Conference (Short Hills, NJ - Feb,1999),
the 57th American Academy of Dermatology Conference (New Orleans, March 1999)
and at the Society of Cosmetic Chemists' Annual Scientific Seminar (Chicago
- May, 1999) is clearly conveyed for your understanding and consideration.
Your consideration and effort to bring understanding and opportunity to our
unique product is deeply appreciated.
Robert Jew, CEO
©2000 Universal Biologics, All Rights Reserved.